The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients.

[pyomyositis]

There are many limitations to the current antibiotics used for the treatment of severe methicillin-resistant Staphylococcus aureus (MRSA ) infections . Ceftaroline is a new fifth -generation cephalosporin approved for the treatment of skin and soft tissue infections caused by MRSA and community-acquired pneumonia . We propose that ceftaroline can also be used successfully in more severe MRSA infections , including endocarditis . We conducted a retrospective chart review in a university-affiliated Department of Veterans Affairs hospital in San Diego , California (USA ) of ten inpatients treated with ceftaroline for severe MRSA infection , including five cases of probable endocarditis (including two endocardial pacemaker infections ), one case of pyomyositis with possible endocarditis , two cases of pneumonia (including one case of empyema ), two cases of septic arthritis (including one case of prosthetic joint infection ), and two cases of osteomyelitis . Seven of the 10 patients achieved microbiological cure . Six of the 10 patients achieved clinical cure . Seven patients were discharged from the hospital . Three patients were placed on comfort care and expired in the hospital ; one achieved microbiological cure before death , and two remained bacteremic at time of death . In most patients , ceftaroline was effective for treatment of MRSA bacteremia and other severe MRSA infections . Adverse effects seen included rash , eosinophilia , pruritus , and Clostridium difficile infection . Ceftaroline can be a safe and effective drug for treatment of severe MRSA infections , and further comparative studies are warranted .

Diseases
Validation

Diseases presenting "septic arthritis" symptom

acute rheumatic fever

familial hypocalciuric hypercalcemia

pyomyositis

This symptom has already been validated